PRESTIGE Study

RPT904 (Ozureprubart) Food Allergy Study

Study Objective: To understand the efficacy of RPT904 (Ozureprubart), a long-acting monoclonal antibody, as a potential treatment for IgE-mediated food allergies such as peanut, milk, egg, cashew, or walnut. RPT904 has the potential to be dosed every 8 to 12 weeks, compared to every 2 or 4 weeks for competitors.

Who is Eligible: Participants 12 to 55 years of age with a confirmed IgE-mediated food allergy to at least one of the following: peanut, milk, egg, cashew, or walnut. Participant eligibility criteria will be confirmed as part of the screening process through skin prick test, IgE, and food challenge results.

Those with uncontrolled asthma, severe eczema, or a history of severe anaphylaxis requiring intubation are not eligible.

Study Duration: Approximately 68 to 72 weeks (about 18 months), including screening, two 24-week treatment periods, and a follow-up phase. Participants will receive subcutaneous injections every 8 or 12 weeks, along with food challenge assessments and laboratory visits.

Study Principal Investigators: Sayantani B. Sindher, MD

Study Sponsor: RAPT Therapeutics, Inc.

Compensation for participation is provided.

View the Full Flyer HERE.

Contact for more information and to schedule a screening visit: Clinic Email: snpcenterallergy.inquiry@stanford.edu

Clinic Phone: (650) 521-7237

For complaints, concerns, or participant's rights, contact 1-877-992-4724.

COMFORT Toddlers Study

DBV712 (Viaskin® Peanut Patch) Food Allergy Study

Study Objective: To understand the safety of DBV712 (Viaskin® Peanut Patch) 250mcg, a epicutaneous immunotherapy, or EPIT, as a potential treatment for IgE-mediated food allergies designed to deliver microgram amounts of allergens to the immune system through intact skin.

Who is Eligible: Children (1-3 years of age) are welcome. Participants must have a peanut allergy diagnosis or be suspected of having a peanut allergy, which will be confirmed by skin prick testing, IgE, and screening food challenge results. Additionally, our physicians will further determine eligibility based on the participant's medical history and other criteria in the clinic.

Those with uncontrolled asthma, severe skin diseases involving the proposed application area (interscapular region), a history of immunotherapy for peanut allergy, or a history of severe anaphylaxis are not eligible.

Study Duration: Taking part in the study involves up to 14 visits to the study site and 8 phone calls. The study lasts from 6 to 24 months and includes a screening period of up to 6 weeks to see if your child is well matched to the study. Toddlers who qualify will be selected at random (like the toss of a coin) to wear either the study active patch or a placebo patch, which looks like the study patch but has no active ingredients, during the first 6 months in the study. During the study you will apply a patch on your child’s back and change the patch every day and keep track of any skin reaction, while keeping your child on a peanut-free diet.

After 6 months, you may continue in the optional extension of the study, in which all participants will receive the active study patch for an additional 18 months. Two weeks after the last patch was used, you will have a follow-up phone call with the study team.

Study Principal Investigator: Sayantani B. Sindher, MD

Study Sponsor: DBV Technologies

Compensation for participation is provided.

View the Full Flyer HERE.

Contact for more information and to schedule a screening visit: Clinic Email: snpcenterallergy.inquiry@stanford.edu

Clinic Phone: (650) 521-7237

For complaints, concerns, or participant's rights, contact:
1-877-992-4724.

COVID FLU

Study Objective: This study aims to understand how your body responds to the flu vaccine if you previously have had COVID-19 and may have other medical conditions.

Who is Eligible: Anyone 13 to 64 years of age who has had COVID-19, Long term COVID-19 (Long COVID), Chronic Fatigue Syndrome, Obesity, and/or Type 2 Diabetes. People who have not had COVID-19 will be included as well.

Study Duration: The study will last 1 month and involve 3 visits. You will receive the flu shot at the first study visit. We will ask you for a blood sample at all visits. There is an optional 6 month visit where we will ask you to return to the clinic for further blood sample collection. Compensation will be provided.

Study Principal Investigator: Sayantani Sindher, MD

Study Sponsor: NIH

Contact for more information:

Clinic Email: snpcenterallergy.inquiry@stanford.edu
Clinic Phone: (650) 521-7237

For complaints, concerns, or participant’s right questions, contact: 1-866-680-2906.

Participate in Prescreening at the Sean N. Parker Center for Allergy & Asthma at Stanford University

Condition: Allergies, Food Allergies, Asthma, Eczema, Atopic Dermatitis, Allergic Rhinitis, Eosinophilic Esophagitis (EOE)

Age Group: 0-90 y/o

Duration: 1 Time Event

Description: We invite people with doctor-diagnosed food allergies, asthma, eczema, allergic rhinitis, eosinophilic esophagitis (EOE), and other allergic conditions to participate in prescreening for allergy and asthma research at our center.

Contact: If you are interested in learning more about the study or scheduling a prescreening visit, you can call us at (650) 521-7237 or contact us at snpcenterallergy.inquiry@stanford.edu

SEAL

SEAL (Stopping Eczema and ALlergy) Study
Study ongoing but no longer recruiting

Study Objective: To test if proactive use of topical skin creams is more effective than common atopic dermatitis (eczema) treatment methods at preventing eczema and food allergies.

Who is Eligible: Any child up to 12 weeks of age is welcomed. Our physicians will determine the participant's eligibility based on the participant's skin and other criteria in the clinic. Parental consent is required prior to enrollment.

Study Duration: 36 months (4 clinic visits)

Study Principal Investigators: Sayantani B. Sindher, MD

Study Sponsor: Stanford University School of Medicine 
Compensation for participation is provided.

Contact for more information and to schedule a pre-screening visit:

Clinic Email:
snpcenterallergy.inquiry@stanford.edu
Clinic Phone: (650) 521-7237